Table 2.
Summary of collated participant characteristics of participants included in present review
| Vigushin et al. 1998 [22] | Ripple et al. 1998 [23] (n = 18) | Ripple et al. 2000 [24] (n = 16) | Bailey et al. 2008 [25] (n = 14) | Miller et al. 2013 [26] (n = 43) | Total (N = 133) |
||
|---|---|---|---|---|---|---|---|
| Phase 1 (n = 32) | Phase 2 (n = 10) |
||||||
| Enrolled participants; n | 32 | 10 | 18 | 19 | 14 | 43 | 136 |
| Evaluable participants n (%) | 32 (100) | 10 (100) | 16 (88.9) | 16 (84.2) | 14 (100) | 40 (93.0) | 128 (94.1) |
| Age; years | |||||||
| Median | 57 | 57 | 58.6a | 50 | 58 | 58.5 | |
| Range | 35–78 | 40–82 | 23–82 | 24–79 | 40–90 | – | 23–90 |
| Sex; n (%) | |||||||
| Male | 15 (46.9) | 0 (0) | 8 (44.4) | 13 (81.3) | 0 (0) | 0 (0) | 36 (27.1) |
| Female | 17 (53.1) | 10 (100) | 10 (55.6) | 6 (37.5) | 14 (100) | 40 (100) | 97 (72.9) |
| Breast cancer; n (%) | 16 (50.0) | 10 (100) | 2 (11.1) | 1(6.3) | 14 (100) | 40 (100) | 83 (62.4) |
| Prior therapies | |||||||
| Surgery | 29 (90.6) | 9 (90.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 38 (28.6) |
| Chemotherapy | 28 (87.5) | 7 (70.0) | 14 (77.8) | 14 (87.5) | 11 (78.6) | 0 (0) | 74 (55.6) |
| Radiation therapy | 23 (71.9) | 7 (70.0) | 9 (50.0) | 9 (56.3) | 0 (0) | 0 (0) | 48 (36.1) |
| Hormone therapy | 20 (62.5) | 10 (100) | 6 (33.3) | 4 (25.0) | 13 (92.9) | 6 (14.0) | 59 (44.4) |
| Supportive therapy | 2 (6.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (1.5) |
| Biologic response modifiers | 0 (0) | 0 (0) | 4 (22.2) | 1 (6.3) | 0 (0) | 0 (0) | 5 (3.8) |
| Endocrine agents | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 7 (50.0) | 0 (0) | 7 (5.3) |
aOnly mean age provided in article
- not provided